Business Context and Reporting Period
Company: eXoZymes Inc. (Nasdaq: EXOZ)
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2026
Event: Entry into a Material Definitive Agreement for an underwritten securities offering.
Key Financial Metrics
| Metric | Value |
|---|---|
| Gross Proceeds | $639,990 |
| Placement Agent Commissions | $44,799 |
| Other Expenses | Approx. $30,000 |
| Net Proceeds | Approx. $565,191 |
| Units Sold | 35,555 |
| Price Per Unit | $18.00 |
| Common Shares Issued | 71,110 |
| Warrants Issued | 35,555 |
Note: The filing does not provide data on revenue, profit, cash flow, margins, or total debt levels.
Material Changes and Transaction Details
The Company closed a securities offering on June 30, 2026, selling units consisting of common stock and warrants. This transaction follows a firm commitment underwriting led by MDB Capital on June 5, 2026, with identical terms.
- Structure: Each Unit contains 2 shares of Common Stock and 1 Warrant to purchase 1 share.
- Valuation: The purchase price per share was effectively $8.99, with the warrant valued at $0.02.
- Placement Agent Compensation: MDB Capital received a warrant to purchase 10,666 shares at an exercise price of $11.24 per share, exercisable from December 30, 2026, through June 30, 2031.
Guidance, Outlook, and Warrant Terms
Use of Proceeds: Net proceeds will fund the development of the N-trans-caffeoyltyramine (NCT) business, next-in-line products, research and development, general corporate purposes, working capital, and capital expenditures.
Warrant Terms:
- Exercise Price: $11.24 per share.
- Commencement Date: June 5, 2027.
- Expiration Date: June 5, 2031.
- Redemption: Callable if the stock trades at or above $17.98 for 20 of 30 trading days after the commencement date.
- Warrant Reset Provision: If the Company sells equity at a price below $8.99 per share before June 5, 2027, the warrant exercise price resets to $0.001. This benefit is contingent on the original purchaser holding the shares for the full period without transfer (with limited exceptions for estate planning or legal transfers).
Investor Verification Checklist
- Verify the exact net proceeds after all transaction expenses are finalized.
- Confirm the dilution impact of the 71,110 new shares and potential future issuance from the 35,555 investor warrants and 10,666 placement agent warrants.
- Monitor the stock price relative to the $8.99 threshold to assess the risk of the warrant exercise price resetting to $0.001.
- Review the full text of the Placement Agent Agreement (Exhibit 10.1) and Investor Agreement (Exhibit 10.5) for specific covenants and restrictions.
- Assess the Company's cash runway given the stated use of proceeds for R&D and NCT business development.